Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCShugeng Gao, Jie He, Ning Li et al.|Journal of Thoracic Oncology|2020Cited by 415
International Interdisciplinary Consensus Meeting on the Evaluation of Developmental Dysplasia of the HipJoseph O’Beirne, Konstantinos Voulgaris, Konstantinos Chlapoutakis et al.|Ultraschall in der Medizin - European Journal of Ultrasound|2019Cited by 102
Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLCFan Zhang, Jie He, Wei Guo et al.|Journal of Thoracic Oncology|2022Cited by 74
Risk-stratified Approach for Never- and Ever-Smokers in Lung Cancer Screening: A Prospective Cohort Study in ChinaFei Wang, Jie He, Zheng Wu et al.|American Journal of Respiratory and Critical Care Medicine|2022Cited by 71
Lung cancer risk prediction models based on pulmonary nodules: A systematic reviewZheng Wu, Jie He, Fei Wang et al.|Thoracic Cancer|2022Cited by 56